Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics (DGX) director Robert B. Carter reported acquiring 6 shares of common stock on 10/21/2025 at $189.089 per share. The shares were obtained through a dividend reinvestment plan eligible for deferred reporting on Form 5 under Rule 16a-6; the transaction was reported early.
After this transaction, Carter beneficially owns 2,698 shares, held directly.
DGX filed a Form 144 notice for a proposed sale of 1,482 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $270,316.80. The approximate sale date is October 22, 2025.
The shares were acquired via restricted stock vesting from the issuer on May 16, 2025 as compensation. As context, 111,242,362 shares were outstanding.
Quest Diagnostics (DGX) filed an 8‑K stating it issued a press release announcing its results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1, dated October 21, 2025.
The filing falls under Item 2.02 (Results of Operations and Financial Condition). Quest Diagnostics’ common stock trades on the NYSE under the symbol DGX.
Quest Diagnostics (DGX) reported higher Q3 2025 results. Net revenues rose to $2,816 million from $2,488 million a year ago, and diluted EPS increased to $2.16 from $1.99. Operating income grew to $386 million, while net income attributable to Quest reached $245 million. Cost of services and SG&A increased alongside revenue growth, and Q3 included $11 million of restructuring and impairment charges.
For the first nine months of 2025, revenue was $8,229 million and diluted EPS was $6.57. Operating cash flow was strong at $1,421 million, funding $369 million of capex, $263 million of dividends, and $150 million of share repurchases (0.9 million shares). Cash ended at $432 million; total assets were $16,197 million and stockholders’ equity was $7,295 million.
DGX repaid $600 million notes that matured in March 2025 and extended its $750 million revolver to April 2030, with a $500 million accordion. The company closed the purchase of select Spectra Laboratories clinical testing assets for $34 million and finalized LifeLabs purchase accounting. As of October 15, 2025, shares outstanding were 111,242,362.
Director Timothy M. Ring reported a non‑derivative change related to deferred compensation in Quest Diagnostics (DGX). On 10/01/2025 he received an accrual of 233 phantom stock units under the company’s Amended and Restated Deferred Compensation Plan for Directors; these units convert to cash payable upon his termination of service as a director. The filing shows 17,036.495 phantom stock units credited in his deferred compensation account as of the transaction date, which includes units from dividend reinvestment transactions exempt from reporting. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. No option exercises, cash purchases, or sales of common stock are reported in this filing.
Wright L. Lassiter III, a director of Quest Diagnostics Inc. (DGX), reported on Form 4 that on 10/01/2025 he received 157 phantom stock units under the company's deferred compensation plan for directors. These phantom units arose from elective deferrals of the director's cash compensation and are payable in cash when the reporting person leaves board service. The filing states the total phantom stock units accrued in his deferred compensation account as of the transaction date include dividend-reinvestment credits exempt from separate reporting. The Form 4 shows zero dollar price for the transaction and indicates indirect ownership treatment for the accrued units.
Quest Diagnostics (DGX) Form 144 filing shows an insider planned sale and recent dispositions. The notice reports an intended sale of 227 common shares through Fidelity Brokerage with an aggregate market value of $42,706 and an approximate sale date of 09/26/2025. The 227 shares were acquired under an option (granted 02/19/2018) and will be paid in cash. The filer also reported two recent sales in the prior three months: 28,288 shares on 09/23/2025 for $5,293,312.79 and 175 shares on 09/24/2025 for $32,729.03. The filer attests not to possess undisclosed material adverse information.
Michael E. Prevoznik, Senior Vice President & General Counsel of Quest Diagnostics (DGX), reported option exercises and subsequent sales executed under a Rule 10b5-1 plan. On 09/23/2025 he exercised 28,288 non-qualified options at an exercise price of $103.57 and sold those 28,288 shares at a weighted-average price of $187.1222, leaving 38,117 shares beneficially owned after that transaction. On 09/24/2025 he exercised 175 options at $103.57 and sold 175 shares at a weighted-average price of $187.023, with total beneficial ownership remaining 38,117 shares. He also holds 5,691 shares indirectly in company retirement plans and retains outstanding options covering 28,288 and 175 shares that vested in installments beginning February 19, 2019.
Form 144 filed for Quest Diagnostics (DGX) reports a proposed sale of common stock and recent related transactions. The notice shows an intended sale of 175 shares through Fidelity Brokerage Services with an aggregate market value of $32,729 and an approximate sale date of 09/24/2025 on the NYSE. The 175 shares were acquired by option exercise on 09/24/2025 with cash payment. The filing also discloses a separate sale on 09/23/2025 by Michael Prevoznik of 28,288 common shares for gross proceeds of $5,293,312.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 procedures.
Quest Diagnostics (DGX) filed a Form 144 notifying a proposed sale of 28,288 common shares through Fidelity Brokerage Services LLC on 09/23/2025 on the NYSE. The filing lists an aggregate market value of $5,293,313.43 and reports 111,823,441 shares outstanding, indicating the sale represents a very small fraction of total shares. The shares are reported as acquired under an option granted 02/19/2018 with acquisition and payment dated 09/23/2025 and payment in cash. The filer certifies they are unaware of undisclosed material adverse information and the notice contains the standard attestation language required by Rule 144.